Scientific Publications - Mitsubishi Tanabe Pharma AmericaMitsubishi Tanabe Pharma America

Intravenous edaravone treatment in ALS and survival: an exploratory, retrospective, administrative claims analysis

Brooks BR, Berry JD, Ciepielewska M, et al. eClinicalMedicine. 2022;52:101590.
doi:10.1016/j.eclinm.2022.101590

View reference
Edaravone administered orally and via nasogastric tube in healthy adults: a comparative bioavailability phase 1 study

Shimizu H, Nishimura Y, Shiide Y. Clin Pharmacol Drug Dev. Published online Oct 12, 2022. doi:10.1002/cpdd.1175

View Reference
Long-term edaravone efficacy in amyotrophic lateral sclerosis: post-hoc analyses of Study 19 (MCI186-19)

Shefner J, Heiman-Patterson T, Pioro EP, et al. Muscle Nerve. 2020;61(2):218-221.
doi:10.1002/mus.26740

View reference
Analysis of the US safety data for edaravone (Radicava^®) from the third year after launch

Genge A, Brooks BR, Oskarsson B, et al. Drugs R D. 2022;22(3):205-211. doi:10.1007/s40268-022-00391-6

View reference
Edaravone efficacy in amyotrophic lateral sclerosis with reduced forced vital capacity: post-hoc analysis of Study 19 (MCI186-19)
[clinical trial NCT01492686]

Brooks BR, Heiman-Patterson T, Wiedau-Pazos M, et al. PloS One. 2022;17(6):e0258614.
doi:10.1371/journal.pone.0258614

View reference
Slowing the loss of physical function in amyotrophic lateral sclerosis with edaravone: post hoc analysis of ALSFRS-R item scores in pivotal study MCI186-19

Brooks BR, Pioro EP, Katz J, et al. Muscle Nerve. 2022;65(2):180-186.
doi:10.1002/mus.27467

View reference
Engaging ALS patients and caregivers (the ALS research ambassadors) to help design the REFINE-ALS biomarker study

Berry JD, Bedlack R, Mathews D, et al. Amyotroph Lateral Scler Frontotemporal Degener. 2021;22(1-2):147-150. doi:10.1080/21678421.2020.1804939

View reference
Evidence for generalizability of edaravone efficacy using a novel machine learning risk-based subgroup analysis tool

Brooks BR, Pioro EP, Beaulieu D, et al. Amyotroph Lateral Scler Frontotemporal Degener. 2022;23(1-2):49-57. doi:10.1080/21678421.2021.1927102

View reference
Clinical staging in amyotrophic lateral sclerosis: analysis of edaravone Study 19

Al-Chalabi A, Chiò A, Merrill C, et al. J Neurol Neurosurg Psychiatry. 2021;92(2):165-171.
doi:10.1136/jnnp-2020-323271

View reference
Treatment persistence among amyotrophic lateral sclerosis patients receiving intravenous edaravone: results from a national infusion center

Hagan M, Ciepielewska M, Harrison A, et al. Poster presented at virtual 31st International Symposium on ALS/MND; December 9-11, 2020.

View reference
Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial

The Writing Group on behalf of the Edaravone (MCI-186) ALS 19 Study Group. Lancet Neurol. 2017;16(7):505-512. doi:10.1016/S1474-4422(17)30115-1

View reference
Post-hoc analyses of the edaravone clinical trials Study 16 and Study 19: a step toward more efficient clinical trial designs in amyotrophic lateral sclerosis

Palumbo JM, Hubble J, Apple S, et al. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(5-6):421-431. doi:10.1080/21678421.2019.1599955

View reference
A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis

The Edaravone (MCI-186) ALS 16 Study Group. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(Sup1):11-19. doi:10.1080/21678421.2017.1363780

View reference

The studies referenced herein are provided for general information only and are not intended as statements about the safety or efficacy of any product.